LungLifeAI uses machine learning and artificial intelligence to reduce analysis time by nearly 70%.
LunglifeAI wanted to increase precision to reduce high false positives rates and reduce missed CTCs in other classes. Additionally, the wanted to reduce the extensive manual observation required which resulted in a high cost and time consuming analysis.
LungLifeAI, a pioneer in LiquidBiopsy® technology, uses machine learning and artificial intelligence to enable life-saving early diagnosis of lung cancer. Persistent’s AI algorithms have reduced analysis time by nearly 70% thereby accelerating LungLife’s efforts to greatly reduce the impact of a disease that claims around 400 lives per day.